News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
173 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (21900)
Month
January (3218)
February (3391)
March (3462)
April (3660)
May (4506)
June (2887)
July (2191)
August (2499)
September (2720)
October (3233)
November (3383)
December (2291)
Day
1 (200)
2 (82)
3 (2)
4 (4)
5 (170)
6 (196)
7 (173)
8 (142)
9 (54)
11 (3)
12 (130)
13 (197)
14 (170)
15 (163)
16 (65)
18 (3)
19 (32)
20 (217)
21 (197)
22 (203)
23 (65)
24 (3)
25 (4)
26 (180)
27 (242)
28 (255)
29 (239)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
11
12
13
14
15
16
18
19
20
21
22
23
24
25
26
27
28
29
Pharm Country
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
Virpax Pharmaceuticals Announces Preliminary Results of Probudur TM Pilot Study with the U.S. Army Institute of Surgical Research.
February 7, 2024
·
6 min read
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
Cybin Inc. today announced that the Japan Patent (“JP”) Office has granted JP patents 2023-500532 and 2023-533436.
February 7, 2024
·
7 min read
Senzime Licensee Fukuda Denshi Launches Integrated TetraGraph Module in Japanese Market
Senzime today announced that Fukuda Denshi, its licensee in the Japanese market, is launching the first integrated TetraGraph module.
February 7, 2024
·
2 min read
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Fusion Pharmaceuticals Inc. today announced that the Company will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024.
February 7, 2024
·
2 min read
Genetown
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
Inhibikase Therapeutics, Inc. today announced preliminary outcomes of the Company’s discussion with the U.S. Food and Drug Administration (FDA) on the path to approval of IkT-001Pro in blood cancers, the Company’s prodrug of the anticancer agent imatinib mesylate.
February 7, 2024
·
7 min read
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.
February 7, 2024
·
3 min read
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
Renexxion Ireland Limited announced that its European Partner, Dr. Falk Pharma GmbH, has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease as the second indication in their licensed territories.
February 7, 2024
·
5 min read
Genetown
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Vor Bio today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
February 7, 2024
·
1 min read
BioForest
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Nautilus Biotechnology, Inc. today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024.
February 7, 2024
·
1 min read
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
Pacira BioSciences, Inc. has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier, Inc.
February 7, 2024
·
4 min read
Previous
6 of 18
Next
